Literature DB >> 2778492

Calmodulin content in human central nervous system tumors.

A J Bridges1, A K Ho.   

Abstract

Benign and malignant brain tumors and normal cerebral cortex were assayed for calmodulin content by enzymatic and radioimmunoassay techniques. Normal cerebral cortex contained more (8.31 +/- 1.27 vs 3.30 +/- 0.42 micrograms/mg protein) calmodulin than the brain tumors. The contents of calmodulin in the malignant glioblastomas were significantly higher than the meningiomas (5.41 +/- 0.31 vs 2.97 +/- 0.16 micrograms/mg protein). These differences were independent of tumor location and persisted when calmodulin content was normalized for DNA rather than protein content. This data supports differences in the tissue calmodulin contents with normal cortex greater than primary malignant tumors greater than benign tumors greater than metastatic tumor tissue.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2778492     DOI: 10.1007/BF00165104

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

1.  Preparation and assay of the Ca2+--dependent modulator protein.

Authors:  R K Sharma; J H Wang
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

2.  Relationship between changes in the calcium dependent regulatory protein and adenylate cyclase during viral transformation.

Authors:  D C LaPorte; S Gidwitz; M J Weber; D R Storm
Journal:  Biochem Biophys Res Commun       Date:  1979-02-28       Impact factor: 3.575

Review 3.  Calmodulin.

Authors:  C B Klee; T H Crouch; P G Richman
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

4.  Increased content of calmodulin in Morris hepatoma 5123 t.c. (h).

Authors:  J W Wei; R A Hickie
Journal:  Biochem Biophys Res Commun       Date:  1981-06       Impact factor: 3.575

Review 5.  Calmodulin plays a pivotal role in cellular regulation.

Authors:  W Y Cheung
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

6.  Calcium: calmodulin and cancer.

Authors:  W E Criss; S Kakiuchi
Journal:  Fed Proc       Date:  1982-05

7.  Regional and subcellular calmodulin content of rat brain.

Authors:  B Hoskins; C K Burton; D D Liu; A B Porter; I K Ho
Journal:  J Neurochem       Date:  1986-01       Impact factor: 5.372

8.  Calmodulin systems in neuronal excitability: a molecular approach to epilepsy.

Authors:  R J DeLorenzo
Journal:  Ann Neurol       Date:  1984       Impact factor: 10.422

9.  Regional distribution of calmodulin activity in rat brain.

Authors:  L W Zhou; J A Moyer; E A Muth; B Clark; M Palkovits; B Weiss
Journal:  J Neurochem       Date:  1985-05       Impact factor: 5.372

10.  Characteristics of the cyclic AMP-phosphodiesterase activator in human brain tumours.

Authors:  L Frattola; N Canal; S M Gaini; C Tonini; M Trabucchi
Journal:  J Neurol Sci       Date:  1981 Nov-Dec       Impact factor: 3.181

View more
  2 in total

1.  Evidence for a calmodulin inhibitory substance(s) isolated from human meningiomas.

Authors:  S D Antle; A K Ho; U P Kalyan-Raman
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

2.  New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.

Authors:  Zsolt Zador; Andrew T King; Nophar Geifman
Journal:  PLoS One       Date:  2018-03-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.